Acurx’s antibiotic candidate shows positive Phase 2b clinical cure data

Acurx Pharmaceuticals announced positive extended clinical cure data for ibezapolstat, its lead antibiotic candidate, from the company’s recently completed Phase 2b clinical trial in patients with CDI. This exploratory endpoint showed that 12 patients who agreed to be followed up to three months following Clinical Cure of their infection, 5 of 5 IBZ patients experienced no recurrence of infection. In the vancomycin control arm of the trial, 7 of 7 patients experienced no recurrence of infection. CEO David Luci stated: “Ibezapolstat continues to demonstrate success compared to a standard of care, oral vancomycin, to treat patients with CDI. We anticipate continued favorable differentiation between the two therapeutic options in 2024. We expect to leverage this success in a $1B plus US CDI global market as we move forward with an international Phase 3 clinical trial mandate. The company also anticipates its price point for ibezapolstat, if approved, could meet or beat other antibiotics recommended for use in treating patients with CDI, thereby providing the whole package of clinical comparability with microbiome health, safety and cost for patients with this life-threatening disease.”